AU Patent

AU2023329168A1 — Prolonged release tofacitinib compositions without functional coating

Assigned to Synthon BV · Expires 2025-03-20 · 1y expired

What this patent protects

The present invention relates to a monolithic tablet composition for oral administration of tofacitinib or a pharmaceutically acceptable salt thereof, without a functional coating.

USPTO Abstract

The present invention relates to a monolithic tablet composition for oral administration of tofacitinib or a pharmaceutically acceptable salt thereof, without a functional coating.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023329168A1
Jurisdiction
AU
Classification
—
Expires
2025-03-20
Drug substance claim
No
Drug product claim
No
Assignee
Synthon BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.